STOCK TITAN
  1. Home
  2. Sec-filings
  3. ENLV
  4. [6-K] Enlivex Ltd. Current Report (Foreign Issuer)

Enlivex (Nasdaq ENLV) to host webinar on capital strategy and RMAT Allocetra

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Enlivex Ltd., an Israel-based longevity company, plans a live investor webinar on July 30, 2026, at 10:00 AM Eastern Time. Management intends to discuss the rationale and intended use of proceeds for a recently announced private placement, the status and strategy of its RAIN protocol-based treasury, and recent clinical progress for its Allocetra™ immunotherapy program.

The agenda covers Enlivex’s prediction markets treasury built around the Rain protocol, including recent milestones and portfolio roadmap, and a clinical update on the ongoing Phase 2b trial of Allocetra™ in age-related knee osteoarthritis. Allocetra™ has recently received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for treating symptomatic knee osteoarthritis in patients aged 64 and older. Forward-looking statements address expectations and risks related to the transaction, the digital asset treasury strategy and RAIN token market dynamics, and future clinical and regulatory outcomes.

Positive

  • Allocetra™ has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for symptomatic knee osteoarthritis in patients aged 64 and older.

Negative

  • None.
Webinar Date and Time July 30, 2026, at 10:00 AM Eastern Time Scheduled timing of Enlivex’s live investor webinar
RMAT Patient Age Criterion 64 and older Age group for which Allocetra™ received RMAT designation in symptomatic knee osteoarthritis
Clinical Trial Phase Phase 2b Ongoing Allocetra™ trial in age-related knee osteoarthritis
Press Release Date July 29, 2026 Date of Enlivex’s announcement of the upcoming webinar
Regenerative Medicine Advanced Therapy (RMAT) designation regulatory
"the recently granted Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration"
A Regenerative Medicine Advanced Therapy (RMAT) designation is a U.S. regulatory status given to certain cell, gene, or tissue-based treatments that show promise for serious conditions and early clinical evidence of benefit. It signals that regulators will provide extra guidance and expedited review steps—like giving a promising project a “fast pass” through some development checkpoints—which can shorten time to market and reduce regulatory risk, making the program more valuable and noteworthy to investors.
prediction markets treasury financial
"Enlivex is a quality longevity company powered by a prediction markets treasury"
A prediction markets treasury is the pool of money, tokens or reserves held by a prediction market platform to pay out winners, provide trading liquidity and cover operating costs. Think of it like the cash register and rainy‑day fund for a betting exchange: its size and composition affect whether promises can be paid, how easily users can trade, and how risky the platform is, so investors watch it to judge solvency and financial health.
Rain protocol technical
"treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum"
digital asset treasury strategy financial
"the anticipated benefits of the Company’s digital asset treasury strategy"
A digital asset treasury strategy is a plan for managing a company's or organization's digital assets, such as cryptocurrencies or digital tokens, to support its financial goals. It involves deciding how to acquire, hold, and use these assets efficiently, much like managing cash or investments, to optimize value and minimize risks. For investors, understanding this strategy helps gauge how well an organization controls its digital resources and its overall financial health.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What event did Enlivex (ENLV) report in its July 2026 Form 6-K?
Enlivex reported that its management will host a live investor webinar on July 30, 2026, to discuss the recently announced private placement, RAIN protocol-based treasury strategy, and recent clinical and regulatory developments for its Allocetra™ immunotherapy program.

When is the Enlivex (ENLV) investor webinar and how can investors register?
The webinar is scheduled for Thursday, July 30, 2026, at 10:00 AM Eastern Time. Investors can register online via the provided link: https://www.redchip.com/webinar/ENLV/82414254076, which directs to the event registration page.

What capital and treasury topics will Enlivex (ENLV) cover in the webinar?
Management plans to explain the rationale and intended use of proceeds from its recently announced private placement and outline how this transaction fits within its long-term treasury strategy built around the Rain protocol and a prediction markets-focused digital asset portfolio.

What is Allocetra™ and what is its clinical status at Enlivex (ENLV)?
Allocetra™ is an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging. Enlivex is running an ongoing Phase 2b trial in age-related knee osteoarthritis and is reporting recent clinical progress that will be further detailed during the webinar.

What RMAT designation did the FDA grant to Enlivex’s (ENLV) Allocetra™ program?
The U.S. FDA recently granted Regenerative Medicine Advanced Therapy (RMAT) designation to Allocetra™ for the treatment of symptomatic knee osteoarthritis in patients aged 64 and older, recognizing the program within the agency’s regenerative medicine framework.

How does Enlivex (ENLV) describe its digital asset treasury and the Rain protocol?
Enlivex describes itself as a quality longevity company powered by a prediction markets treasury. Its treasury strategy is built around the Rain protocol, characterized as leading decentralized prediction markets infrastructure on Arbitrum, with an associated RAIN token market.

What risks and uncertainties does Enlivex (ENLV) highlight in its forward-looking statements?
Enlivex cites risks including failure to realize benefits from the private placement and digital asset treasury, volatility and liquidity of RAIN and other cryptocurrencies, regulatory and tax uncertainty for digital assets, competitive pressures, and uncertain clinical and regulatory outcomes for Allocetra™ despite RMAT designation.

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of: July 2026

 

Commission file number: 001-36578

 

ENLIVEX LTD.

(Translation of registrant’s name into English)

 

14 Einstein Street, Nes Ziona, Israel 7403618

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒        Form 40-F ☐

 

 

 

 

 

 

On July 29, 2026, Enlivex Ltd., a company organized under the laws of the State of Israel (the “Company”), issued a press release announcing that its management team will host a live webinar on Thursday, July 30, 2026, at 10:00 AM Eastern Time to provide investors with additional detail on the Company’s recently announced private placement, the status and strategy of its RAIN treasury, and recent clinical progress for Allocetra™. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

 

Exhibit No.    
     
99.1   Press Release

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Enlivex Ltd.
  (Registrant)
   
  By: /s/ Oren Hershkovitz
  Name:  Oren Hershkovitz
  Title: Chief Executive Officer

 

Date: July 29, 2026

 

2

 

Exhibit 99.1

 

 

 

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

 

Webinar to cover the rationale and value creation potential of the recently announced private placement, an update on Rain protocol milestones, and recent clinical progress for Allocetra™, including its new RMAT designation from the FDA

 

Nes-Ziona, Israel, July 29, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), a quality longevity company powered by a prediction markets treasury, today announced that its management team will host a live webinar on Thursday, July 30, 2026, at 10:00 AM Eastern Time to provide investors with additional detail on the Company’s recently announced private placement (the “Transaction”), the status and strategy of its RAIN treasury, and recent clinical progress for Allocetra™.

 

Webinar Agenda

 

Company management will provide an update across three areas:

 

●Private Placement & Treasury Strategy: the rationale for the Transaction, the Company’s intended use of proceeds, and how the Transaction fits within the Company’s long-term treasury strategy built around the Rain protocol
   
●Rain Protocol Update: current status of the Company’s treasury portfolio and a review of recent milestones and the growth roadmap provided by the Rain Foundation
   
●Clinical Update – Allocetra™: progress of the ongoing Phase 2b trial in age-related knee osteoarthritis, and the recently granted Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for Allocetra™ in the treatment of symptomatic knee osteoarthritis in patients aged 64 and older

 

Webinar Details

 

Date/Time: Thursday, July 30, 2026, at 10:00 AM Eastern Time

 

Registration: https://www.redchip.com/webinar/ENLV/82414254076

 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities.

 

 

 

 

ABOUT ENLIVEX

 

Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem.

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,” and other words of similar meaning, including statements relating to the anticipated benefits and timing of the completion of the proposed Transaction and related transactions and the intended use of proceeds from the Transaction; the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company’s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results, including with respect to the RMAT-designated Allocetra™ program; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, Allocetra™ programs.

 

Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Transaction and the Company’s digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; the risk that RMAT designation does not guarantee a faster development timeline, FDA approval, or that all anticipated benefits of the designation will be realized; and those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law.

 

ENLIVEX CONTACT

 

Shachar Shlosberger, CFO

Enlivex Ltd.

shachar@enlivex.com

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases